Selected article for: "antibody response and HCV vaccine"
Author: Brian G. Pierce; Zhen-Yong Keck; Ruixue Wang; Patrick Lau; Kyle Garagusi; Khadija Elkholy; Eric A. Toth; Richard A. Urbanowicz; Johnathan D. Guest; Pragati Agnihotri; Melissa C. Kerzic; Alexander Marin; Alexander K. Andrianov; Jonathan K. Ball; Roy A. Mariuzza; Thomas R. Fuerst; Steven K.H. Foung
Title: Structure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization
  • Document date: 2020_4_17
    • ID: b6to1v4u_6
    Snippet: Here we report the generation, characterization, and in vivo immunogenicity of novel structurebased designs of the HCV E2 glycoprotein, which is the primary target of the antibody response to HCV and a major vaccine target. Designs were focused on antigenic domain D, which is a key region of E2 targeted by broadly neutralizing antibodies (bNAbs) that are resistant to viral escape (24), as well as antigenic domain A, which is targeted by non-neutr.....
    Document: Here we report the generation, characterization, and in vivo immunogenicity of novel structurebased designs of the HCV E2 glycoprotein, which is the primary target of the antibody response to HCV and a major vaccine target. Designs were focused on antigenic domain D, which is a key region of E2 targeted by broadly neutralizing antibodies (bNAbs) that are resistant to viral escape (24), as well as antigenic domain A, which is targeted by non-neutralizing antibodies (25, 26).

    Search related documents:
    Co phrase search for related documents
    • antibody response and HCV antibody response: 1, 2, 3, 4, 5, 6, 7
    • antibody response and major vaccine target: 1
    • antibody response and non neutralizing antibody: 1, 2, 3, 4, 5, 6, 7
    • antibody response and primary target: 1, 2, 3
    • antibody response and vaccine target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • antibody response and viral escape: 1, 2, 3, 4, 5, 6, 7
    • antibody response and vivo immunogenicity: 1, 2, 3, 4, 5
    • broadly neutralize and viral escape: 1
    • broadly neutralize antibody and viral escape: 1
    • HCV antibody response and viral escape: 1
    • HCV antibody response and vivo immunogenicity: 1
    • major vaccine target and vaccine target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • non neutralizing antibody and primary target: 1, 2
    • primary target and vaccine target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • primary target and viral escape: 1, 2
    • vaccine target and viral escape: 1, 2
    • vaccine target and vivo immunogenicity: 1, 2